Augmentation of antipsychotic drug action by azapirone 5-HT1A receptor partial agonists: a meta-analysis. - Wikidata - awgldk - TriplyDB

Augmentation of antipsychotic drug action by azapirone 5-HT1A receptor partial agonists: a meta-analysis.

Augmentation of antipsychotic drug action by azapirone 5-HT1A receptor partial agonists: a meta-analysis.

http://www.wikidata.org/entity/Q34646717

about

Azapirones versus placebo for panic disorder in adults Azapirones versus placebo for panic disorder in adults Selective serotonin 3 receptor antagonist treatment for schizophrenia: meta-analysis and systematic review.Efficacy and tolerability of topiramate-augmentation therapy for schizophrenia: a systematic review and meta-analysis of randomized controlled trials.HTR1A Polymorphisms and Clinical Efficacy of Antipsychotic Drug Treatment in Schizophrenia: A Meta-Analysis.Thinking and acting beyond the positive: the role of the cognitive and negative symptoms in schizophrenia.Potential serotonergic agents for the treatment of schizophrenia.

P2860

Q24193425-C071F51F-41D2-4A06-A7E5-6F32FB720594 Q24202655-194D2FD9-BB8A-4C04-A928-9CB1B3BC5D10 Q34879435-7DD409DE-00C7-47DB-B52B-067E4D85D2EA Q36232038-36BF0FEF-DF50-4592-A082-2E3F86296618 Q36950578-4848A709-BCF6-4962-A876-9253DB6A472E Q38268878-1C7F642B-8B00-48B5-86F2-C84FBA99DE0C Q38635792-D468D07B-63BF-4743-B80B-FE4010848C76

P2860

Augmentation of antipsychotic drug action by azapirone 5-HT1A receptor partial agonists: a meta-analysis.

http://www.wikidata.org/entity/Q34646717

description

2013 nî lūn-bûn

@nan

2013 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

name

Augmentation of antipsychotic ...... ial agonists: a meta-analysis.

@ast

Augmentation of antipsychotic ...... ial agonists: a meta-analysis.

@en

Augmentation of antipsychotic ...... ial agonists: a meta-analysis.

@nl

type

label

Augmentation of antipsychotic ...... ial agonists: a meta-analysis.

@ast

Augmentation of antipsychotic ...... ial agonists: a meta-analysis.

@en

Augmentation of antipsychotic ...... ial agonists: a meta-analysis.

@nl

prefLabel

Augmentation of antipsychotic ...... ial agonists: a meta-analysis.

@ast

Augmentation of antipsychotic ...... ial agonists: a meta-analysis.

@en

Augmentation of antipsychotic ...... ial agonists: a meta-analysis.

@nl

P1433

Q34646717-293F359E-6A18-4A21-9C97-570A58F99B4B

P1476

Q34646717-2D83783A-8E32-47EB-B4C8-A0B94012777D

P2093

Q34646717-43C44443-BF35-4EE6-87F0-2D0DE1C049C4

Q34646717-AADAC5DB-3679-49FB-8036-5D97AC26B6CD

P2860

Q34646717-053CDCD3-6788-4DEC-B010-582BB6191BCC

Q34646717-19DE4098-0A9C-4298-93CE-1895DD5DE45C

Q34646717-1DB298FD-17E0-438A-AEBD-6B0F3654E24E

Q34646717-2053401F-E1E5-4C5D-B452-D5C9E513BA85

Q34646717-21A1782F-A078-489B-8A35-1434D8FE3D86

Q34646717-21CF1688-7173-4E54-BACF-B95DC9273088

Q34646717-221939FC-E225-488C-9700-2935E7BDEB4D

Q34646717-34EB2FBA-6BD7-4683-9FD9-C95F555EA9D0

Q34646717-4071A240-8A9F-4D57-8352-00FF0AABA166

Q34646717-4C9487DC-6B68-42DE-94BA-2ADAFFE1F4FB

P304

Q34646717-AD877C66-22EA-4AE6-9555-6BA7A1E4AA82

P31

Q34646717-081568A2-3177-4FC0-AF57-AE9FEAB1A831

Q34646717-3b97e522-b98b-4587-a76b-ee2a5b3d441d

P356

Q34646717-F90AAC0E-9109-4D10-A53E-6843B78F9360

P433

Q34646717-F2D4BFF2-878F-45B6-82D5-2FBA195501E1

P478

Q34646717-E1AC1E6B-D2E3-415F-93C9-AB404F013C7F

P50

Q34646717-7939A7E5-94DA-4771-A107-1DB85F31601D

P577

Q34646717-175A1FB5-E012-489E-9B55-C5C9A86E7A60

P698

Q34646717-3688178A-ED10-4BAB-9ECE-76771BAF3E0B

P356

S1461145713000151

P1433

The International Journal of Neuropsychopharmacology

P1476

Augmentation of antipsychotic ...... tial agonists: a meta-analysis

@en

P2093

Herbert Y Meltzer

http://www.w3.org/2001/XMLSchema#string

Taro Kishi

http://www.w3.org/2001/XMLSchema#string

P2860

Measuring inconsistency in meta-analyses

Meta-analysis in clinical trials

Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment

Prevention of the phencyclidine-induced impairment in novel object recognition in female rats by co-administration of lurasidone or tandospirone, a 5-HT(1A) partial agonist.

Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties.

Regulation of 5-HT1A receptor function in brain following agonist or antidepressant administration.

Negative symptoms in schizophrenia. Definition and reliability.

Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs.

Effect of buspirone, a serotonin1A partial agonist, on cognitive function in schizophrenia: a randomized, double-blind, placebo-controlled study.

P304

1259-1266

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1017/S1461145713000151

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-04-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23551924

http://www.w3.org/2001/XMLSchema#string